For a period of about 2 weeks ending last Friday I had been bugging Cortecs regarding the status of the tb antigen diagnostic test. I wish I could give all kinds of sordid details, but I didn't get anything worthwhile except for one. This Friday, Mr. McBeath, Inflazyme's CEO, is meeting with Phil Goodwin, the project manager for the tb diagnostic test development. The IR person for Cortecs told me that Goodwin said they're working on it, but without specifics I don't know what that really means.
I just found out that Mr. McBeath left last night for the U.K., so I guess that answers whom is visiting whom. He will be gone until the "middle of next week". I don't know whether the tb diagnostic test development (or perhaps lack of it, with the possibility that Cortecs may not be meeting their contractual obligations of the November, l996, agreement) is the sole item on his agenda, but it's interesting to think about. By the way, if Cortecs has temporarily shelved the test development due to their own reorganization, perhaps the possibility exists that the test, with some substantial development already done, could revert back to Inflazyme (with IZP perhaps paying Cortecs a royalty for work they've done). This is pure speculation on my part, but we'll probably know the true story in a few weeks.
HL |
